The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Why the idea of an ideal worker can be so harmful for people with mental health conditions
...
Read moreDetailsHome » Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.